Int J Clin Oncol:PembrolizumabVS化疗治疗复发性晚期尿道癌的疗效

2020-07-31 MedSci原创 MedSci原创

开放标签、随机、主动对照的KEYNOTE-045研究(NCT02256436)显示,与标准化疗(紫杉醇、多西他赛或醋氟宁)相比,二线pembrolizumab可显著改善一线含铂化疗后进展的晚期/转移性

开放标签、随机、主动对照的KEYNOTE-045研究(NCT02256436)显示,与标准化疗(紫杉醇、多西他赛或醋氟宁)相比,二线pembrolizumab可显著改善一线含铂化疗后进展的晚期/转移性尿道癌(UC)患者的总生存期(OS)。Pembrolizumab在日本被批准用于膀胱癌患者。

 

在KEYNOTE-045研究中入组的日本患者亚组中进行分析。主要终点为OS和无进展生存期(PFS)。客观反应率(ORR)和安全性为次要终点。

 

结果,52名日本患者(pembrolizumab,n = 30;化疗,n = 22)进行了中位26.1个月的随访。与化疗相比,接受pembrolizumab的患者死亡风险降低了19%(危险比[HR]0.81,95% CI 0.44-1.50);校正基线协变量后,OS的HR为0.61(95% CI 0.32-1.15)。彭博利珠单抗的24个月OS率较高(26.9% vs 14.3%)。pembrolizumab和化疗的PFS分别为2.0和4.9个月(HR 1.71,95% CI 0.95-3.08)。pembrolizumab和化疗的ORR相似(20.0% vs 18.2%);pembrolizumab的反应持久性更高。分别有67%和33%的患者维持反应超过12个月。治疗相关的不良事件,包括3-5级事件,发生在pembrolizumab的频率较低。

 

该结果表明,在总体人群和日本亚组中,pembrolizumab为含铂化疗后进展的局部晚期/转移性UC患者提供了持久的抗肿瘤活性;安全性曲线与之前观察到的pembrolizumab一致。

 

原始出处:

 

Hiroyuki NishiyamaYoshiaki Yamamoto,et al., Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. Int J Clin Oncol. 2020 Jan;25(1):165-174. doi: 10.1007/s10147-019-01545-4.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1769166, encodeId=361e1e691666c, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Wed Jul 07 05:57:26 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912416, encodeId=9ca619124162e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Apr 16 13:57:26 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961850, encodeId=01bc961850c2, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:17:23 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715203, encodeId=2cd71e1520361, content=<a href='/topic/show?id=a03e3803ba' target=_blank style='color:#2F92EE;'>#BVS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3803, encryptionId=a03e3803ba, topicName=BVS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987531903456, createdName=12498e67m38暂无昵称, createdTime=Thu Jun 17 18:57:26 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728617, encodeId=959a1e2861790, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 27 00:57:26 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909832, encodeId=22a11909832da, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Dec 26 01:57:26 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865871, encodeId=42cd18658e1f7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Dec 24 18:57:26 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787014, encodeId=3dd81e87014d4, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14026, encryptionId=38601402654, topicName=Pembro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jun 19 12:57:26 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272555, encodeId=a6c512e2555d2, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14028, encryptionId=4323140286a, topicName=Pembrolizumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379580, encodeId=cb5613e958072, content=<a href='/topic/show?id=755b4e5461b' target=_blank style='color:#2F92EE;'>#尿道癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47546, encryptionId=755b4e5461b, topicName=尿道癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a119458, createdName=neurosurgeon, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
    2021-07-07 lifestar
  2. [GetPortalCommentsPageByObjectIdResponse(id=1769166, encodeId=361e1e691666c, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Wed Jul 07 05:57:26 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912416, encodeId=9ca619124162e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Apr 16 13:57:26 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961850, encodeId=01bc961850c2, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:17:23 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715203, encodeId=2cd71e1520361, content=<a href='/topic/show?id=a03e3803ba' target=_blank style='color:#2F92EE;'>#BVS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3803, encryptionId=a03e3803ba, topicName=BVS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987531903456, createdName=12498e67m38暂无昵称, createdTime=Thu Jun 17 18:57:26 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728617, encodeId=959a1e2861790, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 27 00:57:26 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909832, encodeId=22a11909832da, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Dec 26 01:57:26 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865871, encodeId=42cd18658e1f7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Dec 24 18:57:26 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787014, encodeId=3dd81e87014d4, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14026, encryptionId=38601402654, topicName=Pembro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jun 19 12:57:26 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272555, encodeId=a6c512e2555d2, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14028, encryptionId=4323140286a, topicName=Pembrolizumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379580, encodeId=cb5613e958072, content=<a href='/topic/show?id=755b4e5461b' target=_blank style='color:#2F92EE;'>#尿道癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47546, encryptionId=755b4e5461b, topicName=尿道癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a119458, createdName=neurosurgeon, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
    2021-04-16 snf701207
  3. [GetPortalCommentsPageByObjectIdResponse(id=1769166, encodeId=361e1e691666c, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Wed Jul 07 05:57:26 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912416, encodeId=9ca619124162e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Apr 16 13:57:26 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961850, encodeId=01bc961850c2, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:17:23 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715203, encodeId=2cd71e1520361, content=<a href='/topic/show?id=a03e3803ba' target=_blank style='color:#2F92EE;'>#BVS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3803, encryptionId=a03e3803ba, topicName=BVS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987531903456, createdName=12498e67m38暂无昵称, createdTime=Thu Jun 17 18:57:26 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728617, encodeId=959a1e2861790, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 27 00:57:26 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909832, encodeId=22a11909832da, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Dec 26 01:57:26 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865871, encodeId=42cd18658e1f7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Dec 24 18:57:26 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787014, encodeId=3dd81e87014d4, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14026, encryptionId=38601402654, topicName=Pembro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jun 19 12:57:26 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272555, encodeId=a6c512e2555d2, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14028, encryptionId=4323140286a, topicName=Pembrolizumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379580, encodeId=cb5613e958072, content=<a href='/topic/show?id=755b4e5461b' target=_blank style='color:#2F92EE;'>#尿道癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47546, encryptionId=755b4e5461b, topicName=尿道癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a119458, createdName=neurosurgeon, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
    2021-04-30 MedSciZeng

    #J Clin Oncol#点击查看更多该期刊内容

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1769166, encodeId=361e1e691666c, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Wed Jul 07 05:57:26 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912416, encodeId=9ca619124162e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Apr 16 13:57:26 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961850, encodeId=01bc961850c2, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:17:23 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715203, encodeId=2cd71e1520361, content=<a href='/topic/show?id=a03e3803ba' target=_blank style='color:#2F92EE;'>#BVS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3803, encryptionId=a03e3803ba, topicName=BVS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987531903456, createdName=12498e67m38暂无昵称, createdTime=Thu Jun 17 18:57:26 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728617, encodeId=959a1e2861790, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 27 00:57:26 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909832, encodeId=22a11909832da, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Dec 26 01:57:26 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865871, encodeId=42cd18658e1f7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Dec 24 18:57:26 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787014, encodeId=3dd81e87014d4, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14026, encryptionId=38601402654, topicName=Pembro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jun 19 12:57:26 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272555, encodeId=a6c512e2555d2, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14028, encryptionId=4323140286a, topicName=Pembrolizumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379580, encodeId=cb5613e958072, content=<a href='/topic/show?id=755b4e5461b' target=_blank style='color:#2F92EE;'>#尿道癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47546, encryptionId=755b4e5461b, topicName=尿道癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a119458, createdName=neurosurgeon, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1769166, encodeId=361e1e691666c, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Wed Jul 07 05:57:26 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912416, encodeId=9ca619124162e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Apr 16 13:57:26 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961850, encodeId=01bc961850c2, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:17:23 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715203, encodeId=2cd71e1520361, content=<a href='/topic/show?id=a03e3803ba' target=_blank style='color:#2F92EE;'>#BVS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3803, encryptionId=a03e3803ba, topicName=BVS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987531903456, createdName=12498e67m38暂无昵称, createdTime=Thu Jun 17 18:57:26 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728617, encodeId=959a1e2861790, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 27 00:57:26 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909832, encodeId=22a11909832da, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Dec 26 01:57:26 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865871, encodeId=42cd18658e1f7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Dec 24 18:57:26 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787014, encodeId=3dd81e87014d4, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14026, encryptionId=38601402654, topicName=Pembro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jun 19 12:57:26 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272555, encodeId=a6c512e2555d2, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14028, encryptionId=4323140286a, topicName=Pembrolizumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379580, encodeId=cb5613e958072, content=<a href='/topic/show?id=755b4e5461b' target=_blank style='color:#2F92EE;'>#尿道癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47546, encryptionId=755b4e5461b, topicName=尿道癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a119458, createdName=neurosurgeon, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
    2021-02-27 feather89
  6. [GetPortalCommentsPageByObjectIdResponse(id=1769166, encodeId=361e1e691666c, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Wed Jul 07 05:57:26 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912416, encodeId=9ca619124162e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Apr 16 13:57:26 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961850, encodeId=01bc961850c2, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:17:23 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715203, encodeId=2cd71e1520361, content=<a href='/topic/show?id=a03e3803ba' target=_blank style='color:#2F92EE;'>#BVS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3803, encryptionId=a03e3803ba, topicName=BVS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987531903456, createdName=12498e67m38暂无昵称, createdTime=Thu Jun 17 18:57:26 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728617, encodeId=959a1e2861790, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 27 00:57:26 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909832, encodeId=22a11909832da, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Dec 26 01:57:26 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865871, encodeId=42cd18658e1f7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Dec 24 18:57:26 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787014, encodeId=3dd81e87014d4, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14026, encryptionId=38601402654, topicName=Pembro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jun 19 12:57:26 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272555, encodeId=a6c512e2555d2, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14028, encryptionId=4323140286a, topicName=Pembrolizumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379580, encodeId=cb5613e958072, content=<a href='/topic/show?id=755b4e5461b' target=_blank style='color:#2F92EE;'>#尿道癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47546, encryptionId=755b4e5461b, topicName=尿道癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a119458, createdName=neurosurgeon, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1769166, encodeId=361e1e691666c, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Wed Jul 07 05:57:26 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912416, encodeId=9ca619124162e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Apr 16 13:57:26 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961850, encodeId=01bc961850c2, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:17:23 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715203, encodeId=2cd71e1520361, content=<a href='/topic/show?id=a03e3803ba' target=_blank style='color:#2F92EE;'>#BVS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3803, encryptionId=a03e3803ba, topicName=BVS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987531903456, createdName=12498e67m38暂无昵称, createdTime=Thu Jun 17 18:57:26 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728617, encodeId=959a1e2861790, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 27 00:57:26 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909832, encodeId=22a11909832da, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Dec 26 01:57:26 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865871, encodeId=42cd18658e1f7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Dec 24 18:57:26 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787014, encodeId=3dd81e87014d4, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14026, encryptionId=38601402654, topicName=Pembro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jun 19 12:57:26 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272555, encodeId=a6c512e2555d2, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14028, encryptionId=4323140286a, topicName=Pembrolizumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379580, encodeId=cb5613e958072, content=<a href='/topic/show?id=755b4e5461b' target=_blank style='color:#2F92EE;'>#尿道癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47546, encryptionId=755b4e5461b, topicName=尿道癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a119458, createdName=neurosurgeon, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
    2020-12-24 minlingfeng
  8. [GetPortalCommentsPageByObjectIdResponse(id=1769166, encodeId=361e1e691666c, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Wed Jul 07 05:57:26 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912416, encodeId=9ca619124162e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Apr 16 13:57:26 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961850, encodeId=01bc961850c2, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:17:23 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715203, encodeId=2cd71e1520361, content=<a href='/topic/show?id=a03e3803ba' target=_blank style='color:#2F92EE;'>#BVS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3803, encryptionId=a03e3803ba, topicName=BVS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987531903456, createdName=12498e67m38暂无昵称, createdTime=Thu Jun 17 18:57:26 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728617, encodeId=959a1e2861790, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 27 00:57:26 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909832, encodeId=22a11909832da, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Dec 26 01:57:26 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865871, encodeId=42cd18658e1f7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Dec 24 18:57:26 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787014, encodeId=3dd81e87014d4, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14026, encryptionId=38601402654, topicName=Pembro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jun 19 12:57:26 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272555, encodeId=a6c512e2555d2, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14028, encryptionId=4323140286a, topicName=Pembrolizumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379580, encodeId=cb5613e958072, content=<a href='/topic/show?id=755b4e5461b' target=_blank style='color:#2F92EE;'>#尿道癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47546, encryptionId=755b4e5461b, topicName=尿道癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a119458, createdName=neurosurgeon, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
    2021-06-19 chendoc242
  9. [GetPortalCommentsPageByObjectIdResponse(id=1769166, encodeId=361e1e691666c, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Wed Jul 07 05:57:26 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912416, encodeId=9ca619124162e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Apr 16 13:57:26 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961850, encodeId=01bc961850c2, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:17:23 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715203, encodeId=2cd71e1520361, content=<a href='/topic/show?id=a03e3803ba' target=_blank style='color:#2F92EE;'>#BVS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3803, encryptionId=a03e3803ba, topicName=BVS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987531903456, createdName=12498e67m38暂无昵称, createdTime=Thu Jun 17 18:57:26 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728617, encodeId=959a1e2861790, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 27 00:57:26 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909832, encodeId=22a11909832da, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Dec 26 01:57:26 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865871, encodeId=42cd18658e1f7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Dec 24 18:57:26 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787014, encodeId=3dd81e87014d4, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14026, encryptionId=38601402654, topicName=Pembro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jun 19 12:57:26 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272555, encodeId=a6c512e2555d2, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14028, encryptionId=4323140286a, topicName=Pembrolizumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379580, encodeId=cb5613e958072, content=<a href='/topic/show?id=755b4e5461b' target=_blank style='color:#2F92EE;'>#尿道癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47546, encryptionId=755b4e5461b, topicName=尿道癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a119458, createdName=neurosurgeon, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1769166, encodeId=361e1e691666c, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Wed Jul 07 05:57:26 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912416, encodeId=9ca619124162e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Apr 16 13:57:26 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961850, encodeId=01bc961850c2, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:17:23 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715203, encodeId=2cd71e1520361, content=<a href='/topic/show?id=a03e3803ba' target=_blank style='color:#2F92EE;'>#BVS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3803, encryptionId=a03e3803ba, topicName=BVS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987531903456, createdName=12498e67m38暂无昵称, createdTime=Thu Jun 17 18:57:26 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728617, encodeId=959a1e2861790, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 27 00:57:26 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909832, encodeId=22a11909832da, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Dec 26 01:57:26 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865871, encodeId=42cd18658e1f7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Dec 24 18:57:26 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787014, encodeId=3dd81e87014d4, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14026, encryptionId=38601402654, topicName=Pembro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jun 19 12:57:26 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272555, encodeId=a6c512e2555d2, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14028, encryptionId=4323140286a, topicName=Pembrolizumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379580, encodeId=cb5613e958072, content=<a href='/topic/show?id=755b4e5461b' target=_blank style='color:#2F92EE;'>#尿道癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47546, encryptionId=755b4e5461b, topicName=尿道癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a119458, createdName=neurosurgeon, createdTime=Sun Aug 02 10:57:26 CST 2020, time=2020-08-02, status=1, ipAttribution=)]

相关资讯

Support Care Cancer:多模态运动改善接受化疗的头颈部癌症患者的运动反应和身体成分

研究发现,很多化疗药物会对癌症患者产生多种副作用和并发症,尤其是在心血管疾病方面。本研究旨在探讨运动训练干预能否改善正在接受化疗的头颈部(H&N)癌症患者的身体成分和运动反应。

Cancer Immunol Immunother:混合多肽疫苗组合多烯紫杉醇和地塞米松治疗去势抵抗性前列腺癌研究

之前人们开发了一种包含20种混合多肽(KRM-20)的新的癌症疫苗来诱导细胞毒性T淋巴细胞,从而抵抗12种不同的肿瘤相关的抗原。最近,有研究人员在II期试验中调查了是否KRM-20组合多烯紫杉醇和地塞米松能够在去势抵抗性前列腺癌(CRPC)患者中增强抗肿瘤作用。研究是一个双盲、安慰剂对照和随机II期研究,研究人员在日本10个医疗中心招募了无化疗CRPC患者。符合要求的患者以1:1的比例随机分配在K

Pediatr Blood Cancer:中性粒细胞减少饮食与食品安全指南对小儿肿瘤患者感染率的有效性

中性粒细胞饮食(ND)是为了避免细菌进入宿主的胃肠道,减少感染。由于缺乏支持ND的证据,小儿肿瘤科医生对ND是否有用仍有争议。这项前瞻性随机对照试验评估了随机接受食品和药物管理局批准的食品安全指南(F

Int J Clin Oncol:4天MEA治疗绒癌和高危GTN的疗效

本研究旨在评估4天化疗与甲氨蝶呤、依托泊苷和放线菌素D(MEA)对诊断为绒癌和高危妊娠滋养细胞瘤(GTN)患者的疗效和毒性。

J Clin Oncol:[ 18 F]氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描对头颈癌的分期及在N0颈部的阴性预测价值和手术影响

本研究旨在确定正电子发射断层扫描(PET)/计算机断层扫描(CT)在颈部解剖的基础上对临床N0颈部的负预测值(NPV)。

Virol J:接受化疗的非移植性急性白血病患者合并感染人类疱疹病毒的情况

人类疱疹病毒(HHVs)在原发感染后仍有潜伏期,并可在免疫抑制和化疗后重新激活。对其在非移植性白血病患者中的发病率、潜在关系、危险因素和临床影响知之甚少。本研究调查了初诊急性白血病患者中HHVs-(1